Corcept Therapeutics (CORT) Payables (2010 - 2026)

Corcept Therapeutics has reported Payables for 17 years, with the latest figure at $14.9 million in Q2 2026.

• Quarterly Payables fell 36.62% year-over-year to $14.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.9 million (down 36.62% YoY) and the FY2025 annual result came in at $40.4 million, up 163.03% from the prior year.
• Payables fell to $14.9 million in Q2 2026 per CORT's latest filing, from $33.3 million in the prior quarter.
• Over five years, Payables peaked at $40.4 million in Q4 2025 and troughed at $8.0 million in Q2 2023.
• A 5-year average of $18.4 million and a median of $16.0 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2025 and 2026: Payables surged 163.03% in 2025, then sank 36.62% in 2026.
• Over 5 years, Payables stood at $12.0 million in 2022, then jumped by 45.26% to $17.4 million in 2023, then fell by 11.61% to $15.4 million in 2024, then surged by 163.03% to $40.4 million in 2025, then tumbled by 63.13% to $14.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $14.9 million, $33.3 million, and $40.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.